View profile

FarmaKology Newsletter - Issue #66



January 28 · Issue #66 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+10K Subscribers )!

Today's Startup
Nuvalent, Inc.
Nuvalent, Inc.
Nuvalent, Inc.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
 Eli Lilly and Company and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending doses and clinical pharmacology studies. P2X7 receptors have been consistently implicated in neuroinflammation, a driving force in chronic pain conditions.
Kintor Pharmaceutical Limited is pleased to announce that the clinical trial of Proxalutamide’s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board (“IRB”) of Brazil. The trial was accepted for accelerated review.
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drug candidates for highly prevalent diseases, announced the initiation of an up to $14.5 million projects funded by CARB-X to develop an oral monoclonal antibody cocktail to prevent serious diarrheal diseases. Separately, the company simultaneously published pre-clinical and clinical research describing for the first time how its novel spirulina platform is used to rapidly develop, produce, and deliver edible antibody drugs.
Evotec SE today announced that EVT 894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development.
Research & Study
NutraCast Podcast: Lux Research on digital biomarkers in personalized nutrition by NutraIngredients-USA Podcast
Job Opportunities
Upcoming Webinar
Dr. Baar - Legend Labz MBX200
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue